| CAS NO: | 163252-36-6 |
| 包装 | 价格(元) |
| 50mg | 电议 |
| 10mg | 电议 |
| Cas No. | 163252-36-6 |
| 别名 | 克拉夫定; L-FMAU |
| 化学名 | 1-[(2S,3R,4S,5S)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione |
| Canonical SMILES | CC1=CN(C(=O)NC1=O)C2C(C(C(O2)CO)O)F |
| 分子式 | C10H13FN2O5 |
| 分子量 | 260.22 |
| 溶解度 | DMF: 10 mg/ml,DMSO: 30 mg/ml,PBS (pH 7.2): 5 mg/ml |
| 储存条件 | Store at -20℃, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2]. References: |
m.cnreagent.com